[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab

被引:0
作者
Romain-David Seban
Emilie Arnaud
Delphine Loirat
Luc Cabel
Paul Cottu
Lounes Djerroudi
Segolene Hescot
Pierre Loap
Claire Bonneau
Francois-Clement Bidard
Virginie Huchet
Nina Jehanno
Arnaud Berenbaum
Laurence Champion
Irene Buvat
机构
[1] Department of Nuclear Medicine and Endocrine Oncology,Laboratoire d’Imagerie Translationnelle en Oncologie, Inserm U1288, Institut Curie
[2] Institut Curie,Department of Medical Oncology, Institut Curie
[3] PSL University,Department of Medical Oncology, Institut Curie
[4] Paris Saclay University,Circulating Tumor Biomarkers Laboratory, Institut Curie
[5] PSL Research University,undefined
[6] Department of Pathology,undefined
[7] Institut Curie,undefined
[8] Department of Radiation Oncology,undefined
[9] Institut Curie,undefined
[10] Inserm U900,undefined
[11] Institut Curie,undefined
[12] Department of Surgery,undefined
[13] Institut Curie,undefined
[14] UVSQ/Paris-Saclay University,undefined
[15] SiRIC,undefined
[16] PSL Research University,undefined
[17] Department of Nuclear Medicine,undefined
[18] Institut Curie,undefined
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词
Early triple-negative breast cancer; Neoadjuvant chemotherapy ± pembrolizumab; Pathologic response; [18F]FDG PET/CT; Tumor metabolism; Metabolic tumor burden;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:4024 / 4035
页数:11
相关论文
共 222 条
[1]  
Foulkes WD(2010)Triple-negative breast cancer N Engl J Med 363 1938-1948
[2]  
Smith IE(2021)Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline J Clin Oncol 39 1485-1505
[3]  
Reis-Filho JS(2018)Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis Ann Oncol 29 1497-1508
[4]  
Korde LA(2021)Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis BMJ 375 e066381-654
[5]  
Somerfield MR(2015)Evolving treatment strategies for triple-negative breast cancer J Natl Compr Canc Netw 13 652-5829
[6]  
Carey LA(2018)Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel Clin Cancer Res 24 5820-821
[7]  
Crews JR(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med 382 810-567
[8]  
Denduluri N(2022)Event-free survival with pembrolizumab in early triple-negative breast cancer N Engl J Med 386 556-684
[9]  
Hwang ES(2020)Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial JAMA Oncol 6 676-543
[10]  
Poggio F(2022)Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Ann Oncol 33 534-5461